Neoplasm MetastasisNCT00184275
Characterization of Brain Metastases
An observational study of Neoplasm Metastasis and Lung Neoplasms, run by Norwegian University of Science and Technology at 1 site in Norway.
Trial summary
The purpose is to characterize tumour biological markers in brain metastases tissue from patients with different primary tumour by using ex vivo techniques as high-resolution magic angle spinning MR spectroscopy and micro array. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neoplasm Metastasis, Lung Neoplasms, Breast Neoplasms
- How many people
- 26 participants
- Where
- 1 siteNorway
- Study dates
- May 2005to Dec 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with brain metastases
Who may be able to join
- Clinical diagnosis of brain metastases
Who cannot join
- children
- pregnancy
Trial locations and contacts
1 site in 1 country.
Norway1 site
Norwegian University of Science and Technology, Faculty of Medicine
Trondheim, N-7489
About this study
Official title: Brain Metastases Tissue Characterized by High-resolution Magic Angle Spinning MR and Micro Array
The purpose is to characterize tumour biological markers in brain metastases tissue from patients with different primary tumour by using ex vivo techniques as high-resolution magic angle spinning MR spectroscopy and micro array.
- Conditions
- Neoplasm Metastasis, Lung Neoplasms, Breast Neoplasms, Melanoma
- Keywords
- Brain metastasis, HR MAS spectroscopy, Tissue micro array, DNA micro array
- Medical subject headings
- Neoplasm Metastasis, Lung Neoplasms, Breast Neoplasms, Melanoma, Brain Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2005 (estimated)
- Study startMay 2005
- Primary completionMay 2007
- Study completionDec 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Neoplasm MetastasisStudies of the same condition, open and under way.
- More trials run by Norwegian University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- Norwegian University of Science and Technology
- Sponsor type
- University, hospital or other
- Collaborators
- The Royal Norwegian Ministry of Health
- Responsible party
- Sponsor
- Investigators
- Steinar Lundgren, MD PhD, Study director, Cancer Clinic, St.Olavs Hospital Trondheim University HospitalIngrid S Gribbestad, PhD, Study chair, Norwegian University of Science and Technology, Faculty of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00184275
- Sponsor's protocol ID
- 12621
- Status last verified
- Mar 2014
- First submitted
- 13 Sep 2005
- Last updated
- 7 Mar 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Sjobakk TE, Johansen R, Bathen TF, Sonnewald U, Kvistad KA, Lundgren S, Gribbestad IS. Metabolic profiling of human brain metastases using in vivo proton MR spectroscopy at 3T. BMC Cancer. 2007 Jul 27;7:141. doi: 10.1186/1471-2407-7-141.
PubMed 17662122Sjobakk TE, Vettukattil R, Gulati M, Gulati S, Lundgren S, Gribbestad IS, Torp SH, Bathen TF. Metabolic profiles of brain metastases. Int J Mol Sci. 2013 Jan 22;14(1):2104-18. doi: 10.3390/ijms14012104.
PubMed 23340650
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Brain Metastases Tissue Characterized by High-resolution Magic Angle Spinning MR and Micro Array
- ClinicalTrials.gov ID
- NCT00184275
- Acronym / sponsor ID
- 12621
- Conditions
- Neoplasm Metastasis, Lung Neoplasms, Breast Neoplasms, Melanoma
- Keywords
- Brain metastasis, HR MAS spectroscopy, Tissue micro array, DNA micro array
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- Norwegian University of Science and TechnologyUniversity, hospital or other
- Collaborators
- The Royal Norwegian Ministry of Health
- Study start
- May 2005
- Primary completion
- May 2007 (actual)
- Study completion
- Dec 2010 (actual)
- First posted
- 16 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose is to characterize tumour biological markers in brain metastases tissue from patients with different primary tumour by using ex vivo techniques as high-resolution magic angle spinning MR spectroscopy and micro array.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with brain metastases
Key inclusion criteria (1 listed)
- Clinical diagnosis of brain metastases
Key exclusion criteria (2 listed)
- children
- pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2014.
- Background: PubMed 17662122Sjobakk TE, Johansen R, Bathen TF, Sonnewald U, Kvistad KA, Lundgren S, Gribbestad IS. Metabolic profiling of human brain metastases using in vivo proton MR spectroscopy at 3T. BMC Cancer. 2007 Jul 27;7:141. doi: 10.1186/1471-2407-7-141.
- Results publication: PubMed 23340650Sjobakk TE, Vettukattil R, Gulati M, Gulati S, Lundgren S, Gribbestad IS, Torp SH, Bathen TF. Metabolic profiles of brain metastases. Int J Mol Sci. 2013 Jan 22;14(1):2104-18. doi: 10.3390/ijms14012104.
Related trials for Neoplasm Metastasis
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Not yet recruitingPhase 1
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
Advanced or Metastatic Breast Cancer
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
RecruitingPhase 3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
RecruitingPhase 2
Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma
Soft Tissue Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Steinar Lundgren, MD PhD study director
Cancer Clinic, St.Olavs Hospital Trondheim University Hospital
Ingrid S Gribbestad, PhD study chair
Norwegian University of Science and Technology, Faculty of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neoplasm Metastasis and Lung Neoplasms, run by Norwegian University of Science and Technology at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00184275, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2014; AzTrials last refreshed its copy on 6 Nov 2026.